Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

looking at trades so far today it seems this was one of those , buy on rumour sell on news type, investments .

Just giving these two announcements a little more thought; Classic piece of bad PR. The losses have grabbed the headlines and the Phase III trials are forgotten. Perhaps they should have released the results, let the SP take the hit and then release the good news three or four days later, probably restoring the SP value. Just a thought, never mind, not long until 2006!!

regards

PTH

Taken a hard hit this morning, tend to think it may be this that as spooked holders....................

"In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.". Dilution in one form or another. They were looking very good, perhaps we may get a quick recovery. Dont hold but have been tempted.

cheers GF.

might be a good time to get in gf.

I have taken my profits and run (a little reluctantly!) - but I will be back - if it drops to 9p IMHO it will bounce back

tipped again as a buy in shares mag this week . started to creep back up . looks like people have seen the potential. bad pr excersise making the two announcements together i think.

The words to use are not ' bad PR exercise' - amateurish is more like it,
prices move on perception, they need to be a lot slicker about the way they put across news.

Re post 61 - It did and I did - Is it a bit of a worry that Shares Mag recommend it 3 weeks out of 4 ?

Good write up in the Times today, puts into perspective the 'herd mentality' witnessed following the announcemnt of cash raising required to further the company's ambitions.

regards

PTH

The Sunday Times article:

Biotech chief seeks to end years of pain
By Paul Durman
Alan Goodman of CeNeS hoped good results would change his luck, but he still needs more money



ALAN GOODMAN should be used to disappointment. As one of Britains most experienced biotechnology entrepreneurs, he is only too familiar with the ups and inevitable downs that go with the drug-development business.
Goodman was hoping that last week would mark a new beginning for CeNeS, his pain-treatment company that has endured a troubled three years.



My careers on the line, he said, as he prepared to announce results from late-stage trials of M6G, a treatment for post-operative pain.

I started this (treatment) based on work I discovered in 1992. This is the fruit of 12 years work, several millions of pounds, lots of trauma. Nobody else (in UK biotech) has got a compound from initial discovery through to phase III trials.

If weve got a result, I expect the mainline institutions to invest in it, to say: Jesus, theyve done it.

Last Monday, CeNeS duly announced positive results for M6G, a form of morphine developed to avoid causing the same level of nausea and vomiting.

Goodmans City advisers had hoped that shares in CeNeS would jump by as much as 25%. Instead, the shares weakened as the company said it was considering raising further equity to continue the development of its product.

Analysts close to CeNeS insisted that there was nothing alarming in this. Anyone who followed the company would have understood it needed to perform another phase III trial on M6G to compare it with the gold standard of morphine.

However, CeNeS has recently attracted some hot money from private investors who do not want to wait for a share placing. Hence the fall in the price.

CeNeS may need to raise 8m to 10m, or perhaps 15m if it seeks to avoid licensing M6G to international marketing partners.

Given the size of the market in post-operative pain, believers in the firm insist shares in CeNes look bloody cheap at below 10p. That values the company at only 25m.

CeNeS was briefly a stock- market high-flyer a specialist in pain and neurological disease that Goodman and his team built on the foundations of a moribund Scottish biotech company called Core.

His earlier ventures included the firms that became Chiroscience and Acambis two of the larger and more successful biotech companies to emerge in Britain over the past 15 years.

CeNeSs initial rapid progress came to a grinding halt in 2001. Apart from the collapse of investor confidence in biotech stocks, CeNeS found itself caught up in the severe financial problems and controversy afflicting two much larger drug companies, Elan and Bioglan.

CeNeS had licensed key products to Elan and Bioglan, which had previously been seen as highly successful, fast-growing and profitable businesses Elan was once Irelands most valuable company.

But, within months, both businesses started to unravel amid allegations of dubious accounting practices and exaggerated profits. Bioglan, a FTSE 250 company, quickly fell into administration while Elan embarked on a year-long restructuring programme to stave off insolvency.

That was the nightmare, said Goodman. A company with two major partners going bankrupt. Could we survive it or not? That was touch and go.

CeNeS had no choice but to embark on its own painful restructuring closing research facilities, shedding staff and selling off smaller products to concentrate on its pain treatments. The most important of these is M6G.

CeNeS has overcome numerous obstacles, and is close to delivering a valuable product. But Goodman still needs a bit more time and more money to complete the turnround.

looks like the waters have calmed and the price has done the same, anyone got any update apart from the offering to raise cash for phase 111.

Just bought in today ' 7.37 is this the bottom?

I too am in again. Waited for the SP to reach the recent open offer price of 7.50p and like you did a little better. Past performance would suggest it has bottomed!

We need some positve press comment now

just a thought has anyone got experience/opinion of the time frame for the trials. From phase 2 to phase 3 would be nice. obvious fishing for news to be broken.

watcher

Any views on CEN for 2005? Ten-bagger or 100% loss?!

neither I would have thought. CEN's products are widely thought to be good and any positive news would see a big jump. But all bio's seem to have a habit of promising much more than they actually deliver. At the moment I am holding until I see which direction the newsflow is going

whoops

The good news for this one is that it is holding its own (and no its not a w****r !) despite lack of news = that has not historically been the case with CEN. It will explode !!

Explosion upwards would be good. I'm also in OXB which has been nothing but frustration over the last year so hoping for bigger and better things from CEN.